Amarin Corp Plcuk (AMRN) Accumulated Depreciation & Amortization (2010 - 2025)

Amarin Corp Plcuk (AMRN) reported Accumulated Depreciation & Amortization of $1.5 million for Q4 2025, little changed year-over-year from $1.5 million in Q4 2024, and little changed quarter-over-quarter from $1.5 million in Q4 2024.

Amarin Corp Plcuk (AMRN) Accumulated Depreciation & Amortization (2010 - 2025) Analysis & Trends

Amarin Corp Plcuk (AMRN) has 16 years of Accumulated Depreciation & Amortization data on file, last reported at $1.5 million in Q4 2025.

  • Accumulated Depreciation & Amortization for Q4 2025 came in at $1.5 million, changed 0.27% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.5 million (changed 0.27% YoY), and the FY2025 annual result was $1.5 million, changed 0.27% from the prior year.
  • Accumulated Depreciation & Amortization was little changed at $1.5 million in Q4 2025 per AMRN's latest filing, from $1.5 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $2.5 million in Q4 2022 and troughed at $1.4 million in Q4 2023.
  • A 5-year average of $1.7 million and a median of $1.5 million in 2025 frame the typical range for Accumulated Depreciation & Amortization.
  • The sharpest annual moves came in 2022 and 2023: Accumulated Depreciation & Amortization climbed 28.68% in 2022, then sank 44.22% in 2023.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $1.9 million in 2021, then increased by 28.68% to $2.5 million in 2022, then slumped by 44.22% to $1.4 million in 2023, then advanced by 6.6% to $1.5 million in 2024, then advanced by 0.27% to $1.5 million in 2025.
  • Business Quant data shows AMRN's Accumulated Depreciation & Amortization at $1.5 million in Q4 2025, $1.5 million in Q4 2024, and $1.4 million in Q4 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn
10 Amarin Corp Plcuk 5.84 Bn 5.66 Bn 17.77 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 1.47 Mn
Dec 31, 2025 1.47 Mn
Dec 31, 2024 1.47 Mn
Dec 31, 2024 1.47 Mn
Dec 31, 2023 1.38 Mn
Dec 31, 2023 1.38 Mn
Dec 31, 2022 2.47 Mn
Dec 31, 2022 2.47 Mn
Dec 31, 2021 1.92 Mn
Dec 31, 2021 1.92 Mn
Dec 31, 2020 1.62 Mn
Dec 31, 2020 1.62 Mn
Dec 31, 2019 1.02 Mn
Dec 31, 2019 1.02 Mn
Dec 31, 2018 839,000.00
Dec 31, 2018 839,000.00
Dec 31, 2017 816,000.00
Dec 31, 2017 816,000.00
Dec 31, 2016 743,000.00
Dec 31, 2016 743,000.00